In the past three months, four analysts have provided ratings on Metagenomi (NASDAQ:MGX), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target is $12.25, down from a previous $14.75. Analysts have adjusted their ratings and price targets in response to market conditions, with some lowering their targets. Metagenomi, a genetic medicines company, has shown significant revenue growth but lags behind industry peers. The company maintains a strong financial position with effective debt management.